Gilead's lenacapavir could be the most significant HIV prevention advance in years. But at over $42,000 per year in the US, access remains out of reach for most. Here's how China's expanding PrEP ecosystem stacks up.
On April 3, 2026, researchers at Johns Hopkins University published an analysis on subscription-based pricing for lenacapavir — Gilead Sciences' twice-yearly injectable HIV prevention drug. The paper arrived at a awkward time, given the drug's US list price of approximately $42,250 per year. That number puts it well out of reach for most people who could benefit.
Lenacapavir, sold as Sunlenca, works differently from daily oral PrEP. Instead of a pill every day, patients get two injections per year. Clinical trials showed it outperformed daily Truvada, and it's widely regarded as one of the biggest HIV prevention advances in years. The catch: that price tag.
Even with insurance, cost-sharing can be brutal. In low- and middle-income countries, Gilead has negotiated tiered pricing, but critics say those deals are still too expensive for widespread use.
Subscription pricing — where a government or insurer pays a flat annual fee for all covered individuals — has been floated as a way to fix this. The model guarantees volume; manufacturers accept lower per-unit prices while still recouping R&D costs. Similar approaches have been discussed for antibiotics and other expensive drugs.
Whether the US actually adopts subscription pricing for lenacapavir is an open question. But the debate exposes a familiar tension: the most promising HIV prevention tool in years is priced for the wealthy. That tension is exactly what medical tourism tries to exploit.
China's HIV prevention infrastructure has grown considerably over the past decade. The country has been expanding access to both PrEP and PEP (post-exposure prophylaxis), with real effort on affordability.
For daily oral PrEP, China relies on generic TDF/FTC — the same combination as Truvada. Domestic generic versions cost as little as ¥50–¥200 (about $7–$28) per month through the public healthcare system. That's a fraction of what the same drugs cost in the US, and it makes oral PrEP accessible to a much wider population. China's NMPA has approved these generics for HIV prevention specifically, and they're available at designated hospitals and clinics in major cities.
Lenacapavir received NMPA approval in China in late 2023, but only for HIV treatment, not prevention. As of early 2026, the drug is in the early stages of treatment rollout in China, and clinical trials for its use as PrEP are underway at research centers in several cities. Chinese biotech companies are also exploring biosimilar versions, which could bring costs down further if approved.
China's public health system offers PrEP through designated AIDS clinics, often at subsidized rates or free for high-risk groups. The country has invested heavily in outreach and testing, which feed into PrEP consultations. Online platforms now offer telemedicine PrEP prescriptions, which helps with the stigma issue that keeps many people away from in-person visits.
For international patients, services are accessible, though a medical coordinator helps — especially for navigating English-speaking specialists. Beijing, Shanghai, Guangzhou, and Shenzhen all have hospitals and clinics with dedicated international HIV care programs.
| Factor | United States | China |
|---|---|---|
| Key PrEP Option | Daily oral Truvada/Descovy; injectable lenacapavir (Sunlenca) approved 2021 | Daily generic TDF/FTC (widely available); lenacapavir approved for treatment (2023), PrEP trials ongoing |
| Annual Drug Cost | Lenacapavir: ~$42,250/year (list price); oral PrEP: ~$1,800–$2,000/year without insurance | Generic TDF/FTC: ~$85–$340/year through public system; lenacapavir pricing TBD pending broader rollout |
| Dosing Convenience | Lenacapavir: twice-yearly injection; oral PrEP: daily pill | Currently daily oral only (injection unavailable for PrEP as of early 2026) |
| Insurance Coverage | Variable; many plans cover oral PrEP; lenacapavir coverage inconsistent | Basic urban职工医保/居民医保 covers significant portion of PrEP costs; varies by city |
| Public Health Programs | Ready-to-use PrEP subsidised through some state programs; federal PrEP program limited | National PrEP program expanding; free/subsidized PrEP at designated clinics for high-risk groups |
| Access for Foreign Patients | Generally accessible with insurance or out-of-pocket payment; no residency requirement | Accessible at international clinics in major cities; medical tourism coordinators available |
| Clinical Trial Access | Some lenacapavir PrEP trials ongoing; limited enrollment for non-residents | Active lenacapavir PrEP trials in Beijing, Shanghai, and Guangzhou; international enrollment possible |
| Telemedicine for PrEP | Widely available; many platforms offer online prescriptions | Growing rapidly; major platforms offer PrEP consultations and home delivery |
Whether you're exploring PrEP options, seeking HIV specialist care, or looking for a medical coordinator in China, our team can connect you with English-speaking specialists and appropriate facilities. Get in touch for a free consultation.
Get a Free Consultation